Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; hydrochloric acid; water for injections; sodium hydroxide; sodium chloride - supraventricular tachycardia - esmolol noridem is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol noridem is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol noridem is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 125 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 75 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; powdered cellulose; trehalose dihydrate; hyprolose; carmellose sodium; sodium sulfate; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; trehalose dihydrate; hyprolose; sodium sulfate; powdered cellulose; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.